Cipla trades in green post rights for Vysov

Cipla has acquired the brand name and trademark rights for Vysov and Vysov M (vildagliptin + metformin), which are anti-diabetic drugs. Post this development, the stock was trading in green during the early trading session.

In the Indian market, Vysov is commonly known as Vildagliptin. Previously in an agreement with Novartis, Cipla had been co-marketing Vildagliptin under the brand names Vysov and Vysov M. In the last few years, the drug has received strong consumer support, leading to an increased demand, making it easily available across the whole country.

Vildagliptin is an orally active, potent, and selective DPP-4 inhibitor, which basically improves glycemic control in patients by enhancing pancreatic (α and β) islet functions. Strong clinical data supports the wide recommendation and prescription of this antidiabetic medicine for adults having type 2 diabetes mellitus. Currently, the market size of Vildagliptin in India is Rs. 818 crore, as per IQVIA MAT November 2019.

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and other key regulated and emerging markets.

On Tuesday in the early trading session, stock of Cipla was trading Rs 465.45, up by 1.49 per cent or Rs 6.85 per share. The 52-week high is Rs 585.50 and 52-week low is Rs 389.55 on the BSE.